These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21648219)

  • 1. Medicines agencies too often under the influence of drug companies.
    Prescrire Int; 2011 Apr; 20(115):108. PubMed ID: 21648219
    [No Abstract]   [Full Text] [Related]  

  • 2. [Increased commercial financing of national Medical Product Agencies within the EU].
    Ramel B
    Lakartidningen; 2003 Jan; 100(5):338-9. PubMed ID: 12607381
    [No Abstract]   [Full Text] [Related]  

  • 3. The innovative medicines initiative: a European response to the innovation challenge.
    Goldman M
    Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European medicines agency: riddled with conflicts of interest.
    Prescrire Int; 2012 Nov; 21(132):278. PubMed ID: 23210268
    [No Abstract]   [Full Text] [Related]  

  • 5. On the prohibition of conflicts of interest in pharmaceutical regulation: precautionary limits and permissive challenges. A commentary on Sismondo (66:9, 2008, 1909-14) and O'Donovan and Lexchin.
    Abraham J
    Soc Sci Med; 2010 Mar; 70(5):648-51. PubMed ID: 20056525
    [No Abstract]   [Full Text] [Related]  

  • 6. [The Medical Product Agency's work and economics--a comment].
    Ahlqvist Rastad J; Salmonson T
    Lakartidningen; 2003 Jan; 100(5):345. PubMed ID: 12607382
    [No Abstract]   [Full Text] [Related]  

  • 7. Prohibiting or 'managing' conflict of interest? A review of policies and procedures in three European drug regulation agencies.
    Lexchin J; O'Donovan O
    Soc Sci Med; 2010 Mar; 70(5):643-7. PubMed ID: 19782458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunshine at the European regulator.
    Sukkar E
    BMJ; 2012 Feb; 344():e976. PubMed ID: 22337754
    [No Abstract]   [Full Text] [Related]  

  • 9. Secrecy and transparency of medicines licensing in the EU.
    Abraham J; Lewis G
    Lancet; 1998 Aug; 352(9126):480-2. PubMed ID: 9708771
    [No Abstract]   [Full Text] [Related]  

  • 10. European ombudsman questions European Medicines Agency over AbbVie redactions.
    Watson R
    BMJ; 2014 Nov; 349():g6904. PubMed ID: 25406123
    [No Abstract]   [Full Text] [Related]  

  • 11. [Drug control within the EEC I: coordination during the 1990's].
    Strandberg K
    Lakartidningen; 1992 Jan; 89(3):100-1. PubMed ID: 1734132
    [No Abstract]   [Full Text] [Related]  

  • 12. Euro MPs refuse to approve medicines agency's accounts until they tighten rules on conflicts of interest.
    Watson R
    BMJ; 2012 May; 344():e3495. PubMed ID: 22597355
    [No Abstract]   [Full Text] [Related]  

  • 13. [Standards for commercialization of medications in the European Union].
    Benzi G
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 1):33-7. PubMed ID: 12497878
    [No Abstract]   [Full Text] [Related]  

  • 14. New law introduces tougher rules on drug regulation in France.
    Benkimoun P
    BMJ; 2011 Dec; 343():d8309. PubMed ID: 22194407
    [No Abstract]   [Full Text] [Related]  

  • 15. Medicines to remain with European Commission health directorate.
    Watson R
    BMJ; 2014 Oct; 349():g6514. PubMed ID: 25355097
    [No Abstract]   [Full Text] [Related]  

  • 16. European Medicines Agency is attacked over proposal to allow technology assessment bodies to sell advice to drug industry.
    Wise J
    BMJ; 2014 Jul; 349():g4674. PubMed ID: 25033980
    [No Abstract]   [Full Text] [Related]  

  • 17. Can the Food and Drug Administration ensure that our pharmaceuticals are safely manufactured?
    Hubbard WK
    Arch Intern Med; 2009 Oct; 169(18):1655-6. PubMed ID: 19822821
    [No Abstract]   [Full Text] [Related]  

  • 18. Regulating manufacturer-affiliated communication in the information age.
    Schulman KA; Abernethy DR; Rathore SS; Woosley RL
    Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664
    [No Abstract]   [Full Text] [Related]  

  • 19. Industrial interests versus public health: the gap is growing.
    Prescrire Int; 2004 Apr; 13(70):71-6. PubMed ID: 15148985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The European Medicines Agency is still too close to industry.
    Garattini S
    BMJ; 2016 May; 353():i2412. PubMed ID: 27154140
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.